

**PRESS RELEASE**  
**2011 third-quarter revenue**

Villepinte, 26 October 2011

**Consolidated Group revenue (IFRS)**

In thousands of euros	2011	2010	Change
First quarter .....	95,053	86,684	+9.7%
Second quarter .....	98,559	92,220	+6.9%
Third quarter .....	87,138	82,797	+5.2%
<b>Total.....</b>	<b>280,750</b>	<b>261,701</b>	<b>+7.3%</b>

**Consolidated revenue by region**

In thousands of euros	2011	2010	Change
European subsidiaries.....	198,215	190,610	+4.0%
Other markets.....	82,535	71,090	+16.1%
<b>Total.....</b>	<b>280,750</b>	<b>261,701</b>	<b>+7.3%</b>

**2011 third-quarter sales highlights and full-year outlook**

In the third quarter, Dotarem registered continued growth (+12.6% in value) with consistent performances across Europe and further gains in other markets. Over the same period, Xenetix experienced an acceleration with sales growth of 7.7%, particularly from momentum outside of Europe (+12.6%).

Year-to-date for the nine-month period ended 30 September, sales grew 7.3% driven by Dotarem (+15.3%), Lipiodol (+55.0%) and Xenetix (+3.7%). Asia, Latin America and North America accounted for 60% of total growth.

Since the beginning of the year, no production incidents were experienced adversely affecting activity. For year end, the trend of the first nine months is expected to be confirmed.

**Contact:** Administrative and Finance Department - Tel.: 01 45 91 50 69